Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives

Cancer Treat Rev. 2024 Feb:123:102675. doi: 10.1016/j.ctrv.2023.102675. Epub 2023 Dec 25.

Abstract

Desmoid tumors (DT) are rare, slow-growing, locally invasive soft tissue tumors that often pose significant therapeutic challenges. Traditional management strategies including active surveillance, surgery, radiotherapy, and systemic therapy which are associated with varying recurrence rates and high morbidity. Given the challenging nature of DT and the modest outcomes associated with current treatment strategies, there has been a growing interest in the field of γ-secretase inhibitors as a result of its action on the Wnt/β-catenin signaling pathway. In this review article, we will shed the light on the pathogenesis and molecular biology of DT, discuss its symptoms and diagnosis, and provide a comprehensive review of the traditional therapeutic approaches. We will also delve into the mechanisms of action of γ-secretase inhibitors, its efficacy, and the existing preclinical and clinical data available to date on the use of these agents, as well as the potential challenges and future prospects in the treatment landscape of these tumors.

Keywords: Cancer; GIST; Gamma secretase; Sarcoma; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Amyloid Precursor Protein Secretases / therapeutic use
  • Fibromatosis, Aggressive* / drug therapy
  • Fibromatosis, Aggressive* / pathology
  • Humans

Substances

  • Amyloid Precursor Protein Secretases